|
|
Volumn 10, Issue 12, 2011, Pages 890-
|
|
Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBOHYDRATE;
GLYCOLIPID;
GMI 1070;
GMI-1070;
SELECTIN;
BIOMIMETICS;
DRUG DESIGN;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
HUMAN;
METABOLISM;
NOTE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
SYNTHESIS;
BIOMIMETICS;
CARBOHYDRATES;
CLINICAL TRIALS, PHASE I AS TOPIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
DRUG DESIGN;
DRUG DISCOVERY;
DRUG INDUSTRY;
GLYCOLIPIDS;
HUMANS;
SELECTINS;
|
|
EID: 84856062692
PISSN: None
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3622 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|